Cargando…

Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers

Xp11.2 translocation renal cell carcinoma (tRCC), involving transcription factor E3 (TFE3) gene fusions, is a rare and aggressive RCC variant when present in adults and has been recently recognized as a unique entity in RCC. Biomarkers and treatment guidelines do not exist for patients with aggressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jee Soo, Lee, Myung Eun, Jang, Won Sik, Kim, Jongchan, Park, Se Mi, Ham, Won Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869331/
https://www.ncbi.nlm.nih.gov/pubmed/35203530
http://dx.doi.org/10.3390/biomedicines10020321
_version_ 1784656472376868864
author Park, Jee Soo
Lee, Myung Eun
Jang, Won Sik
Kim, Jongchan
Park, Se Mi
Ham, Won Sik
author_facet Park, Jee Soo
Lee, Myung Eun
Jang, Won Sik
Kim, Jongchan
Park, Se Mi
Ham, Won Sik
author_sort Park, Jee Soo
collection PubMed
description Xp11.2 translocation renal cell carcinoma (tRCC), involving transcription factor E3 (TFE3) gene fusions, is a rare and aggressive RCC variant when present in adults and has been recently recognized as a unique entity in RCC. Biomarkers and treatment guidelines do not exist for patients with aggressive Xp11.2 tRCC. The aim was to identify and evaluate therapeutic biomarkers for aggressive Xp11.2 tRCC. RNA sequencing was performed using formalin-fixed, paraffin-embedded tissues from 11 adult patients with clinical T1N0M0 Xp11.2 tRCC, including three patients with aggressive characteristics (recurrence or cancer-specific death after nephrectomy). Thirty genes were differentially expressed between the aggressive and non-aggressive groups, even after adjustment, and were associated with KEGG pathways related to the aggressiveness of Xp11.2 tRCC. PIK3R2, involved in various KEGG pathways, including the PI3K/AKT/mTOR pathway, was overexpressed in the Xp11.2 tRCC cell lines UOK120 and UOK146. The PI3K pathway inhibitor LY294002 showed a significant therapeutic benefit. This study provides the first candidate biomarker, PIK3R2, for aggressive clinical T1N0M0 Xp11.2 tRCC. Furthermore, this study is the first to recommend a targeted drug, LY294002, for aggressive Xp11.2 tRCC based on the molecular pathophysiology.
format Online
Article
Text
id pubmed-8869331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88693312022-02-25 Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers Park, Jee Soo Lee, Myung Eun Jang, Won Sik Kim, Jongchan Park, Se Mi Ham, Won Sik Biomedicines Article Xp11.2 translocation renal cell carcinoma (tRCC), involving transcription factor E3 (TFE3) gene fusions, is a rare and aggressive RCC variant when present in adults and has been recently recognized as a unique entity in RCC. Biomarkers and treatment guidelines do not exist for patients with aggressive Xp11.2 tRCC. The aim was to identify and evaluate therapeutic biomarkers for aggressive Xp11.2 tRCC. RNA sequencing was performed using formalin-fixed, paraffin-embedded tissues from 11 adult patients with clinical T1N0M0 Xp11.2 tRCC, including three patients with aggressive characteristics (recurrence or cancer-specific death after nephrectomy). Thirty genes were differentially expressed between the aggressive and non-aggressive groups, even after adjustment, and were associated with KEGG pathways related to the aggressiveness of Xp11.2 tRCC. PIK3R2, involved in various KEGG pathways, including the PI3K/AKT/mTOR pathway, was overexpressed in the Xp11.2 tRCC cell lines UOK120 and UOK146. The PI3K pathway inhibitor LY294002 showed a significant therapeutic benefit. This study provides the first candidate biomarker, PIK3R2, for aggressive clinical T1N0M0 Xp11.2 tRCC. Furthermore, this study is the first to recommend a targeted drug, LY294002, for aggressive Xp11.2 tRCC based on the molecular pathophysiology. MDPI 2022-01-29 /pmc/articles/PMC8869331/ /pubmed/35203530 http://dx.doi.org/10.3390/biomedicines10020321 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Park, Jee Soo
Lee, Myung Eun
Jang, Won Sik
Kim, Jongchan
Park, Se Mi
Ham, Won Sik
Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers
title Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers
title_full Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers
title_fullStr Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers
title_full_unstemmed Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers
title_short Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers
title_sort gene expression analysis of aggressive adult xp11.2 translocation renal cell carcinoma at clinical stage t1n0m0 to identify potential prognostic and therapeutic biomarkers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869331/
https://www.ncbi.nlm.nih.gov/pubmed/35203530
http://dx.doi.org/10.3390/biomedicines10020321
work_keys_str_mv AT parkjeesoo geneexpressionanalysisofaggressiveadultxp112translocationrenalcellcarcinomaatclinicalstaget1n0m0toidentifypotentialprognosticandtherapeuticbiomarkers
AT leemyungeun geneexpressionanalysisofaggressiveadultxp112translocationrenalcellcarcinomaatclinicalstaget1n0m0toidentifypotentialprognosticandtherapeuticbiomarkers
AT jangwonsik geneexpressionanalysisofaggressiveadultxp112translocationrenalcellcarcinomaatclinicalstaget1n0m0toidentifypotentialprognosticandtherapeuticbiomarkers
AT kimjongchan geneexpressionanalysisofaggressiveadultxp112translocationrenalcellcarcinomaatclinicalstaget1n0m0toidentifypotentialprognosticandtherapeuticbiomarkers
AT parksemi geneexpressionanalysisofaggressiveadultxp112translocationrenalcellcarcinomaatclinicalstaget1n0m0toidentifypotentialprognosticandtherapeuticbiomarkers
AT hamwonsik geneexpressionanalysisofaggressiveadultxp112translocationrenalcellcarcinomaatclinicalstaget1n0m0toidentifypotentialprognosticandtherapeuticbiomarkers